Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry

Ayala Gutiérrez, María del Mar; Rubio-Rivas, Manuel; Romero Gómez, Carlos; Montero Sáez, Abelardo; Pérez de Pedro, Iván; Homs, Narcís; Ayuso García, Blanca; Cuenca Carvajal, Carmen; Arnalich Fernández, Francisco; Beato Pérez, José Luis; Vargas Núñez, Juan Antonio; Letona Giménez, Laura; Suárez Fernández, Carmen; Méndez Bailón, Manuel; Tuñón de Almeida, Carlota; González Moraleja, Julio; de Guzmán García-Monge, Mayte; Helguera Amezua, Cristina; Fidalgo Montero, María del Pilar; Giner Galvañ, Vicente; Gil Sánchez, Ricardo; Collado Sáenz, Jorge; Boixeda, Ramon; Ramos Rincón, José Manuel; Gómez Huelgas, Ricardo

(1) Objectives: To describe the clinical characteristics and clinical course of hospitalized patients with COVID-19 and autoimmune diseases (ADs) compared to the general population. (2) Methods: We used information available in the nationwide Spanish SEMI-COVID-19 Registry, which retrospectively compiles data from the first admission of adult patients with COVID-19. We selected all patients with ADs included in the registry and compared them to the remaining patients. The primary outcome was all-cause mortality during admission, readmission, and subsequent admissions, and secondary outcomes were a composite outcome including the need for intensive care unit (ICU) admission, invasive and non-invasive mechanical ventilation (MV), or death, as well as in-hospital complications. (3) Results: A total of 13,940 patients diagnosed with COVID-19 were included, of which 362 (2.6%) had an AD. Patients with ADs were older, more likely to be female, and had greater comorbidity. On the multivariate logistic regression analysis, which involved the inverse propensity score weighting method, AD as a whole was not associated with an increased risk of any of the outcome variables. Habitual treatment with corticosteroids (CSs), age, Barthel Index score, and comorbidity were associated with poor outcomes. Biological disease-modifying anti-rheumatic drugs (bDMARDs) were associated with a decrease in mortality in patients with AD. (4) Conclusions: The analysis of the SEMI-COVID-19 Registry shows that ADs do not lead to a different prognosis, measured by mortality, complications, or the composite outcome. Considered individually, it seems that some diseases entail a different prognosis than that of the general population. Immunosuppressive/immunoregulatory treatments (IST) prior to admission had variable effects.